"Opportunities for R&D Collaboration with the US National Institutes of Health"…KPBMA to Hold Webinar on the 10th

[Asia Economy Reporter Lee Gwan-joo] Domestic pharmaceutical and bio companies will have the opportunity to participate in the global research and development (R&D) projects of the U.S. National Institutes of Health (NIH).

The Korea Pharmaceutical and Bio-Pharma Manufacturers Association announced on the 7th that it will hold a 'KPBMA/NIH Webinar' online via Zoom from 9 a.m. on the 10th of this month for its member companies.

Under the theme "Find your Collaboration Opportunity," this webinar will highlight NIH's R&D strategies and support projects, providing a platform to explore collaboration opportunities with domestic companies.

The webinar will be conducted with presentations by Michael Selgelar, Director General of the Research and Development Marketing Division at the Technology Transfer Center (TTC) of the U.S. National Cancer Institute (NCI), covering an introduction to NIH ▲ business development opportunities with NIH ▲ NIH's technology portfolio ▲ NIH collaboration cases ▲ benefits and considerations when collaborating with NIH, followed by a live Q&A session.

The NIH, a U.S. federal government agency, supports the world's largest scale of R&D investment in the life sciences field. The 27 institutes and research centers under NIH, including the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID), allocate over 80% of their institutional budgets to NIH research conducted by more than 2,500 universities and companies worldwide, with the scale reaching trillions of won.

Examples of successful commercialization supported by NIH include Gardasil, a cervical cancer prevention vaccine by U.S. MSD (annual sales of $3.6 billion), Prezista, an AIDS treatment by U.S. Janssen (annual sales of $2.2 billion), and Velcade, an anticancer drug by Japan's Takeda Pharmaceutical (annual sales of $1.3 billion).

NIH currently holds a diverse technology portfolio including small molecules, vaccines, biopharmaceuticals, digital health, diagnostic reagents and tools, and possesses not only basic research but also clinical research projects. This is expected to provide a new opportunity platform for domestic pharmaceutical and bio companies and bio ventures with relevant capabilities. An association official said, "We hope that domestic pharmaceutical and bio companies will use NIH support programs based on their respective competitiveness to enhance their global technological competitiveness."

This content was produced with the assistance of AI translation services.